Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

VIZIMPRO DIN 02486032

Status: Cancelled Post Market
Holder: PFIZER CANADA ULC
Molecule: DACOMITINIB (DACOMITINIB MONOHYDRATE)

Health Canada record

Active ingredient(s)DACOMITINIB (DACOMITINIB MONOHYDRATE) 30 MG
Dosage formTablet
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCL01EB07 DACOMITINIB
Original market date22-Apr-2019
Current status date24-Nov-2021
SourceHealth Canada DPD

Establishment licence of the holder

Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing DACOMITINIB (DACOMITINIB MONOHYDRATE)

DINProductCompanyFormStrengthStatus
02486024VIZIMPROPFIZER CANADA ULCTabletDACOMITINIB (DACOMITINIB MONOHYDRATE) 15 MGCancelled Post Market
02486040VIZIMPROPFIZER CANADA ULCTabletDACOMITINIB (DACOMITINIB MONOHYDRATE) 45 MGCancelled Post Market

Notices of Compliance

NOCDateSubmissionReason
218982019-02-26New Drug Submission (NDS)
Request a quote for VIZIMPRO

How to read a Canadian DIN record